● Home  

● Random  

● Nearby  



● Log in  



● Settings  



● Donate  



● About Wikipedia  

● Disclaimers  



Wikipedia





Alvameline





● Article  
● Talk  


● Language  

● Watch  

● Edit  


(Redirected from Lu 25109)
  

Alvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist[1] that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials[2] and was subsequently discontinued.

Alvameline
Clinical data
ATC code
  • None
Identifiers

  • 3-(2-ethyltetrazol-5-yl)-1-methyl-5,6-dihydro-2H-pyridine

CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H15N5
Molar mass193.254 g·mol−1
3D model (JSmol)

  • n1nn(nc1\C2=C\CCN(C)C2)CC

  • InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3 checkY

  • Key:RNMOMKCRCIRYCZ-UHFFFAOYSA-N checkY

  (verify)

See also

edit

References

edit
  1. ^ Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J (June 1998). "In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro". Psychopharmacology. 137 (3): 233–240. doi:10.1007/s002130050615. PMID 9683000. S2CID 20740372. Archived from the original on 2000-10-02. Retrieved 2009-12-03.
  • ^ Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler NR (1998). "A bridging study of LU 25-109 in patients with probable Alzheimer's disease". Life Sciences. 62 (3): 195–202. doi:10.1016/S0024-3205(97)01087-4. PMID 9488097.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Alvameline&oldid=1217263858"
      



    Last edited on 4 April 2024, at 20:01  





    Languages

     


    ●فارسی
     ●Српски / srpski
     ●Srpskohrvatski / српскохрватски
     ●中文
      

     Wikipedia


    ●This page was last edited on 4 April 2024, at 20:01 (UTC).
    ●Content is available under CC BY-SA 4.0 unless otherwise noted.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Terms of Use
    ●Desktop